POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia

POC Study of Pipamperone 15mg Added to Stable Risperidone or Paliperidone Treatment in Chronic Schizophrenic and Schizoaffective Patients With Residual Symptoms: a Phase I/IIa, Randomized, Double-blind, Placebo-controlled Trial of 7 Weeks

This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or paliperidone (PAL) on functional MRI tests and clinical outcome of chronic schizophrenic patients with residual, so-called 'positive' symptoms, as well as on cognition, motivation, subjective well-being of patients, negative symptoms, general psychopathological symptoms and safety/tolerability.

Study Overview

• Status: Completed
• Conditions: Schizoaffective Disorder; Chronic Schizophrenia
• Intervention / Treatment: Drug: Placebo; Drug: Pipamperone

Detailed Description

This exploratory study of 7 weeks was intended to be performed in 40 to 60 patients in up to 10 centers in Belgium. In a subset of patients, the 6-week treatment phase will be preceded by a single-dose cross-over phase with 1 week of wash-out. While the objective of the study, due to its exploratory design, is to assess any effect of the study medication on MRI or clinical outcome, the study medication is expected to improve the residual (remaining) positive symptom(s) of patients. In addition, genetic and pharmacokinetic testing may be performed to learn more about the disorder and its treatment.

• Study Type: Interventional
• Enrollment (Actual): 7
• Phase: Phase 2

Contacts and Locations

Study Locations

• Belgium
  • Kortenberg, Belgium
    • University Psychiatric Institute Sint-Jozef

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent.
• Patient understands the investigational nature of the trial and is willing and able to comply with the trial requirements.
• Patient is male or female, aged 18-65 years.
• Patients has Schizophrenia or Schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-R criteria. Diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI)
• Patient is being treated during at least 12 weeks with a stable dosage of either risperidone depot of 12.5-50mg IM every 2 weeks, paliperidone depot of 25-100mg IM every 4 weeks, risperidone oral administration of 2-6 mg/d, or paliperidone oral administration of 4-12 mg/d
• Patient has a CGI-S score of 3 (mildly ill) or more at baseline.
• Patient has a score of 4 or more on at least 1 item of the positive PANSS subscale (residual symptoms).

Exclusion Criteria:

• Acute exacerbation of schizophrenic or schizoaffective disorder during the past 12 weeks.
• Documented debility or an IQ below 85.
• Comorbid axis 1 conditions (including anxiety disorders, eating disorders, impulse control disorders) requiring drug treatment over the previous 12 weeks.
• Patient has taken, in the past 6 weeks prior to randomization, any newly initiated psychoactive drug.
• Patient was withdrawn from psychoactive drug treatment in the past week or within a period shorter than 5x the elimination half-life of any psychoactive drug. Withdrawal of any prior antipsychotic treatment should not have occurred within 6 weeks prior to baseline.
• Concomitant treatment with any additional antipsychotic drug at a therapeutic dosage, diuretics, QT prolongation drugs, or dopamine agonists.
• Formal cognitive psychotherapy initiated during study treatment or within 6 weeks prior to randomization.
• Patient has any other medical or psychiatric condition, which in the opinion of the investigator, can jeopardize or would compromise the patient's ability to participate in this trial or that would interfere with trial assessments.
• Patient with a DSM-IV alcohol or substance dependence diagnosis (within the last 6 months), an alcohol or substance abuse diagnosis (within the last month) or having a positive standard screen for alcohol or drugs (including benzodiazepines and opioids).
• 'Any concomitant psychoactive treatment (including psychotherapy)' or 'Patient received, in the 6 weeks prior to randomization any newly prescribed psychoactive drug'.
• Patient is pregnant, nursing, or is a woman of child-bearing potential who is not surgically sterile, 2 years postmenopausal, or who does not consistently use 2 combined effective methods of contraception (including at least 1 barrier method), unless sexually abstinent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
PLACEBO_COMPARATOR: Placebo; Sugar pill	Drug: Placebo; matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
EXPERIMENTAL: Pipamperone; 15 mg once daily	Drug: Pipamperone; 15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL; Other Names: Risperdal, Invega and Xeplion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in functional MRI tests	MRI = Magnetic Resonance Imaging Functional tests performed during MRI include the N-Back Test and the Monetary Incentive Delay (MID) Task Test	1 day, 2 weeks and 6 weeks after study treatment start

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in residual PANSS item(s)	PANSS = Positive and Negative Syndrome Scale	2 weeks and 6 weeks after study treatment start
Change from baseline in SWN score and subitem scores	SWN = Subjective Well-being under Neuroleptics questionnaire	2 weeks and 6 weeks after study treatment start
Change from baseline in IMI-SR score and subitem scores	IMI-SR = Intrinsic Motivation Inventory for Schizophrenia Research (questionnaire)	2 weeks and 6 weeks after study treatment start
CGI-I score	CGI-I = Clinical Global Impression if Improvement	2 weeks and 6 weeks after study treatment start
Change from baseline in BARS total and subitem scores	BARS = Barnes Akathisia Rating Scale	6 weeks after study treatment start
Change from baseline in BACS score and subitem scores	BACS = Brief Assessment of Cognition Scale	1 day, 2 weeks and 6 weeks after study treatment start

Collaborators and Investigators

• Sponsor: PharmaNeuroBoost N.V.
• Investigators: Principal Investigator: Marc De Hert, M.D., PhD, University Psychiatric Institute Sint-Jozef Leuvensesteenweg 517 B-3070 Kortenberg, Belgium

Study record dates

Study Major Dates

• Study Start: March 1, 2012
• Primary Completion (ACTUAL): November 1, 2012
• Study Completion (ACTUAL): December 1, 2012

Study Registration Dates

• First Submitted: October 7, 2011
• First Submitted That Met QC Criteria: October 11, 2011
• First Posted (ESTIMATE): October 12, 2011

Study Record Updates

• Last Update Posted (ESTIMATE): November 19, 2014
• Last Update Submitted That Met QC Criteria: November 18, 2014
• Last Verified: November 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia; Psychotic Disorders; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Antipsychotic Agents; Tranquilizing Agents; Psychotropic Drugs; Serotonin Agents; Serotonin Antagonists; Pipamperone
• Other Study ID Numbers: PNB02-C201; 2011-004494-81 (EUDRACT_NUMBER)